Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:HELP

Cybin Q1 2025 Earnings Report

Cybin logo
$10.99 +0.46 (+4.38%)
As of 01:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q1 2025
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cybin-help-33-1-hiring-141809832.html
Cybin continues rally following CEO appointment, up another 13%
August 5 at 6:10 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4626635-cybin-continues-rally-following-ceo-appointment-up-another-13
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
August 6 at 1:00 AM  |  Chaikin Analytics (Ad)
Helus Pharma Appoints Former Intra-Cellular Therapies President Michael Halstead as CEO Ahead of Key HLP003 Phase 3 Readout
August 3 at 7:50 AM  |  quiverquant.comQ
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
August 3 at 7:40 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337414/0/en/helus-pharma-appoints-michael-halstead-as-chief-executive-officer.html
Cybin Inc. (NASDAQ:HELP) Receives Consensus Recommendation of "Buy" from Analysts
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30933663
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review.

Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways.

As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines.

View Cybin Profile
Earnings Tools